Precision medicine delivered by novel drug delivery systems, ranging from sensors to dose printers, could eventually revolutionize the pharmaceutical industry. Although many of these technologies are years away from commercialization, their ability to provide exact dosing with slow sustained release and more targeted therapy should improve patient compliance and outcomes.

Is the general uptrend in India's contract manufacturing segment sustainable, despite some sentiment-dampening run-ins with regulators over compliance concerns?

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

Sanofi appoints chief patient officer; DSM names new leaders; marketing VP leaves Immunotec; Nutrition Zone names president; NAI names VP global sales; Kyowa Hakko USA hires sales manager; KonaRed appoints CFO, board member; Deloitte adds director of research.